Drug Profile
Iberdomide - Celgene Corporation
Alternative Names: CC-220; IBER; Iberdomide hydrochlorideLatest Information Update: 03 Dec 2019
Price :
$50
*
At a glance
- Originator Celgene Corporation
- Class Anti-inflammatories; Antineoplastics; Isoindoles; Piperidones; Skin disorder therapies; Small molecules
- Mechanism of Action CRBN protein modulators; Ubiquitin protein ligase complex modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Systemic lupus erythematosus
- Phase I/II Multiple myeloma
- Discontinued Cutaneous lupus erythematosus; Haematological malignancies; Sarcoidosis; Systemic scleroderma
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 30 Jul 2019 Celgene Corporation plans a pivotal trial in Multiple myeloma (Second-line therapy or greater)
- 03 Jun 2019 Efficacy and adverse events data from a phase I/II trial in Multiple myeloma released by Celgene Corporation